EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A 600 mg of fixed‐dose linezolid in renally impaired patients versus 15 mg/kg intermittent dose‐optimized vancomycin in renally non‐impaired patients: A single centre retrospective analysis for adult patients with hospital‐acquired pneumonia due to methicillin‐resistant Staphylococcus aureus

Mengqin Wang iD, Xiao Liu iD, Zhaoxing Tian iD

Tropical Medicine & International Health · 2023

DOI: 10.1111/tmi.13866 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Tropical Medicine & International Health, 2023. Verfasst von Mengqin Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Emergency Department, JiShuiTan Hospital, Beijing, China. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Pneumonia, Staphylococcal, Cross Infection, Healthcare-Associated Pneumonia. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Both linezolid and vancomycin are approved by USFDA and IDSA guidelines for the management of nosocomial pneumonia due to methicillin‐resistant Staphylococcus aureus (MRSA) in clinical practice. Baseline creatinine clearance is the criterion for prescribing vancomycin or linezolid for hospital‐acquired pneumonia in our institution. However, patients with renal function impairment are far more difficult to manage in intensive care. Thus, the objectives of the study were to compare the clinical efficacy and safety of 600 mg of fixed‐dose linezolid with intermittent dose‐optimised vancomycin in hospital‐acquired pneumonia due to MRSA and to evaluate parameters of clinical cure.

Methods

Analysis of a review of patients' charts. Patients with creatinine clearance

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methicillin-Resistant Staphylococcus aureusPneumonia, StaphylococcalCross InfectionHealthcare-Associated PneumoniaRenal InsufficiencyHumansAdultLinezolidVancomycinAnti-Bacterial AgentsRetrospective StudiesCreatinineTreatment OutcomeHospitals

Stichwörter der Autor:innen

hospital-acquired pneumonialinezolidmethicillin-resistant Staphylococcus aureusnephrotoxicityvancomycin

Substanzen

LinezolidVancomycinAnti-Bacterial AgentsCreatinine

Autor:innen und Institutionen

  • Emergency Department, JiShuiTan Hospital, Beijing, China.

ORCID-Profile: Mengqin Wang, Xiao Liu, Zhaoxing Tian

Zitieren

APA

Wang, M., Liu, X., & Tian, Z. (2023). A 600 mg of fixed‐dose linezolid in renally impaired patients versus 15 mg/kg intermittent dose‐optimized vancomycin in renally non‐impaired patients: A single centre retrospective analysis for adult patients with hospital‐acquired pneumonia due to methicillin‐resistant Staphylococcus aureus. Tropical Medicine & International Health. https://doi.org/10.1111/tmi.13866

Vancouver

Wang M, Liu X, Tian Z. A 600 mg of fixed‐dose linezolid in renally impaired patients versus 15 mg/kg intermittent dose‐optimized vancomycin in renally non‐impaired patients: A single centre retrospective analysis for adult patients with hospital‐acquired pneumonia due to methicillin‐resistant Staphylococcus aureus. Tropical Medicine & International Health. 2023. doi:10.1111/tmi.13866

BibTeX
@article{Wang2023,
  author = {Wang, Mengqin and Liu, Xiao and Tian, Zhaoxing},
  title = {A 600 mg of fixed‐dose linezolid in renally impaired patients versus 15 mg/kg intermittent dose‐optimized vancomycin in renally non‐impaired patients: A single centre retrospective analysis for adult patients with hospital‐acquired pneumonia due to methicillin‐resistant Staphylococcus aureus},
  journal = {Tropical Medicine & International Health},
  year = {2023},
  doi = {10.1111/tmi.13866}
}
Kostenlos starten →